Targeting of Rac GTPases blocks the spread of intact human breast cancer

Oncotarget

Volumn 3, Issue 6, 2012, Pages 608-619

  Katz, Elad ^a   Sims, Andrew H ^a   Sproul, Duncan ^a,b   Caldwell, Helen ^a   Michael Dixon, J ^a   Meehan, Richard R ^a,b   Harrison, David J ^a,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Breast cancer; GTPases; Invasion; Rac1; STAT3

Indexed keywords

ANTIMETASTATIC AGENT; EHT 1864; MESSENGER RNA; RAC1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANTIGEN RETRIEVAL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 84868019264     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.520     Document Type: Article

References (61)

1. Wirtz D, Konstantopoulos K and Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011; 11(7):512-522.
2. Sonnenschein C and Soto AM. The death of the cancer cell. Cancer Res. 2011; 71(13):4334-4337.
3. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(46):18708-18713.
4. Leeper AD, Farrell J, Dixon JM, Wedden SE, Harrison DJ and Katz E. (2011). Long-term culture of human breast cancer specimens and their analysis using optical projection tomography. J Vis Exp, pp. e3085.
5. Leeper AD, Farrell J, Williams LJ, S. TJ, Dixon JM, Wedden SE, Harrison DJ and Katz E. Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture. Biomaterials. 2012; 33(3):907-915.
6. Montell DJ. Morphogenetic cell movements: diversity from modular mechanical properties. Science. 2008; 322(5907):1502-1505.
7. Zuo Y, Shields SK and Chakraborty C. Enhanced intrinsic migration of aggressive breast cancer cells by inhibition of Rac1 GTPase. Biochem Biophys Res Commun. 2006; 351(2):361-367.
8. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z and Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436(7047):123-127.
9. Koh MS and Moon A. Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells. Biochem Biophys Res Commun. 2011; 406(1):25-29.
10. Weber GF, Bjerke MA and DeSimone DW. Integrins and cadherins join forces to form adhesive networks. J Cell Sci. 2011; 124(Pt 8):1183-1193.
11. Yagi S, Matsuda M and Kiyokawa E. Suppression of Rac1 activity at the apical membrane of MDCK cells is essential for cyst structure maintenance. EMBO reports. 2012.
12. Arulanandam R, Vultur A, Cao J, Carefoot E, Elliott BE, Truesdell PF, Larue L, Feracci H and Raptis L. Cadherincadherin engagement promotes cell survival via Rac1/ Cdc42 and signal transducer and activator of transcription-3. Mol Cancer Res. 2009; 7(8):1310-1327.
13. Akhtar N and Streuli CH. Rac1 links integrin-mediated adhesion to the control of lactational differentiation in mammary epithelia. J Cell Biol. 2006; 173(5):781-793.
14. Jeanes AI, Wang P, Moreno-Layseca P, Paul N, Cheung J, Tsang R, Akhtar N, Foster FF, Brennan K and Streuli CH. Specific β-containing integrins exert differential control on proliferation and 2D collective cell migration in mammary epithelial cells. The Journal of Biological Chemistry. 2012 [Epub ahead of print].
15. Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa MS and Kazanietz MG. Rac signaling in breast cancer: A tale of GEFs and GAPs. Cell Signal. 2011; 24(2):353-362.
16. Mira JP, Benard V, Groffen J, Sanders LC and Knaus UG. Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway. Proc Natl Acad Sci U S A. 2000; 97(1):185-189.
17. Fritz G, Brachetti C, Bahlmann F, Schmidt M and Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002; 87(6):635-644.
18. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M and Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000; 19(26):3013-3020.
19. Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Desire L, Slingerland J and Burnstein KL. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr Relat Cancer. 2011; 18(2):207-219.
20. Walker MP, Zhang M, Le TP, Wu P, Laine M and Greene GL. RAC3 is a pro-migratory co-activator of ERalpha. Oncogene. 2011; 30(17):1984-1994.
21. Wang SE, Shin I, Wu FY, Friedman DB and Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor β. Cancer Res. 2006; 66(19):9591-9600.
22. Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE and Kazanietz MG. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell. 2010; 40(6):877-892.
23. Stebel A, Brachetti C, Kunkel M, Schmidt M and Fritz G. Progression of breast tumors is accompanied by a decrease in expression of the Rho guanine exchange factor Tiam1. Oncol Rep. 2009; 21(1):217-222.
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6):515-527.
25. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, Sahai E and Marshall CJ. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008; 135(3):510-523.
26. Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ and Katz E. Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clin Exp Metastasis. 2011; 28(8):811-818.
27. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F and Der CJ. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007; 282(49):35666-35678.
28. Nethe M, Anthony EC, Fernandez-Borja M, Dee R, Geerts D, Hensbergen PJ, Deelder AM, Schmidt G and Hordijk PL. Focal-adhesion targeting links caveolin-1 to a Rac1-degradation pathway. J Cell Sci. 2010; 123(Pt 11):1948-1958.
29. Katz E, Dubois-Marshall S, Sims AH, Gautier P, Caldwell H, Meehan RR and Harrison DJ. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS ONE. 2011; 6(2):e17083.
30. Clinchy B, Gazdar A, Rabinovsky R, Yefenof E, Gordon B and Vitetta ES. The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice. Breast Cancer Res Treat. 2000; 61(3):217-228.
31. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH and Guan KL. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science. 2000; 290(5489):144-147.
32. Yoshida T, Zhang Y, Rivera Rosado LA, Chen J, Khan T, Moon SY and Zhang B. Blockade of Rac1 activity induces G(1) cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol Cancer Ther. 2010; 9(6):1657-1668.
33. Arulanandam R, Geletu M, Feracci H and Raptis L. Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration. Exp Cell Res. 2010; 316(5):875-886.
34. Faruqi TR, Gomez D, Bustelo XR, Bar-Sagi D and Reich NC. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci U S A. 2001; 98(16):9014-9019.
35. Schust J, Sperl B, Hollis A, Mayer TU and Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & biology. 2006; 13(11):1235-1242.
36. Yang C, Liu Y, Leskow FC, Weaver VM and Kazanietz MG. Rac-GAP-dependent inhibition of breast cancer cell proliferation by {β}2-chimerin. J Biol Chem. 2005; 280(26):24363-24370.
37. Yang C, Klein EA, Assoian RK and Kazanietz MG. Heregulin β1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. Biochem J. 2008; 410(1):167-175.
38. Klein EA, Campbell LE, Kothapalli D, Fournier AK and Assoian RK. Joint requirement for Rac and ERK activities underlies the mid-G1 phase induction of cyclin D1 and S phase entry in both epithelial and mesenchymal cells. J Biol Chem. 2008; 283(45):30911-30918.
39. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE, Jr. Stat3 as an oncogene. Cell. 1999; 98(3):295-303.
40. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006; 12(1):11-19.
41. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C and Lin J. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growthsuppressive activity in human cancer cells. Neoplasia (New York, NY. 2010; 12(1):39-50.
42. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM and Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007; 104(18):7391-7396.
43. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN and Yu D. Breast Cancer Metastasis: Challenges and Opportunities. Cancer Res. 2009; 69(12):4951-4953.
44. Ito Y, Iwase T and Hatake K. Eradication of breast cancer cells in patients with distant metastasis: the finishing touches? Breast Cancer. 2011.
45. Benitah SA, Espina C, Valerón PF and Lacal JC. Rho GTPases in human carcinogenesis: a tale of excess. Rev Oncol. 2003; 5(2):70-78.
46. Lozano E, Frasa MA, Smolarczyk K, Knaus UG and Braga VM. PAK is required for the disruption of E-cadherin adhesion by the small GTPase Rac. J Cell Sci. 2008; 121(Pt 7):933-938.
47. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S and Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol. 1999; 19(11):7519-7528.
48. McDonald SL and Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer. 2009; 101(2):209-214.
49. Matos P and Jordan P. Increased Rac1b expression sustains colorectal tumor cell survival. Mol Cancer Res. 2008; 6(7):1178-1184.
50. Lee HO, Silva AS, Concilio S, Li YS, Slifker M, Gatenby RA and Cheng JD. Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res. 2011; 71(20):6327-6337.
51. Li A, Ma Y, Yu X, Mort RL, Lindsay CR, Stevenson D, Strathdee D, Insall RH, Chernoff J, Snapper SB, Jackson IJ, Larue L, Sansom OJ and Machesky LM. Rac1 Drives Melanoblast Organization during Mouse Development by Orchestrating Pseudopod- Driven Motility and Cell-Cycle Progression. Dev Cell. 2011; 21(4):722-734.
52. Tobin NP, Sims AH, Lundgren KL, Lehn S and Landberg G. Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer. 2011; 11:417.
53. Kreuzaler PA, Staniszewska AD, Li W, Omidvar N, Kedjouar B, Turkson J, Poli V, Flavell RA, Clarkson RW and Watson CJ. Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol. 2011; 13(3):303-309.
54. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A and Frank DA. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009; 7(6):966-976.
55. Yue P and Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs. 2009; 18(1):45-56.
56. Raptis L, Arulanandam R, Geletu M and Turkson J. The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res. 2011; 317(13):1787-1795.
57. Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS, Morse MA, Clay TM and Lyerly HK. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res. 2011; 71(13):4380-4391.
58. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ and Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33(20):e175.
59. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31(4):e15.
60. Johnson WE, Li C and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8(1):118-127.
61. Sims AH, Smethurst GJ, Hey Y, Okoniewski MJ, Pepper SD, Howell A, Miller CJ and Clarke RB. The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. BMC Med Genomics. 2008; 1:42.